Liver disease is one of the leading causes of death in HIV-infected individuals from Europe and North America and has been attributed mainly to coinfection with hepatotropic viruses. Little data, however, has so far become available on liver disease in HIV-infected individuals from Africa. Results from a first study on liver disease staging by Fibroscan® in a large group of HIV-infected patients from rural Uganda suggest unexpectedly high rates of advanced fibrosis. These results were independent from hepatitis status, initiating a discussion on the need for future liver disease monitoring in these particular patient groups.
References
1.
RockstrohJ.K., MocroftA., SorianoV.Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis2005; 192: 992–1002.
2.
KonopnickiD., MocroftA., de WitS.Hepatitis B and HIV: prevalence, AIDS progression, response to HAART and increased mortality in the EuroSIDA cohort. AIDS2005; 19: 593–601.
3.
RockstrohJ.K., SpenglerU., SudhopT.Immunosuppression may lead to progression of hepatitis C virus-associated liver disease in hemophiliacs coinfected with HIV. Am J Gastroenterol1996; 91: 2563–2568.
4.
ThioC.L., SeabergE., SkolaskyR.HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter AIDS Cohort Study (MACS). Lancet2002; 360: 1921–1926.
5.
WeberR., SabinC., Friis-MollerN.Liver-related deaths in persons with the human immunodeficiency virus: the D:A:D study. Arch Intern Med2006; 166: 1632–1641.
6.
RosenthalE., PialouxG., BernardN.Liver-related mortality in human-immunodeficiency-virus-infected patients between 1995 and 2003 in the French GERMIVIC Joint Study Group Network (MORTAVIC 2003 Study). J Viral Hepat2007; 14: 183–188.
7.
SpenglerU., LichterfeldM., RockstrohJ.K.Antiretroviral drug toxicity – a challenge for the hepatologist?J Hepatol2002; 36: 283–294.
8.
SorianoV., PuotiM., Garcia-GascoP.Antiretroviral drugs and liver injury. AIDS2008; 22: 1–13.
9.
MadhavaV., BurgessC., DruckerE.Epidemiology of chronic hepatitis C virus infection in sub-Saharan Africa. Lancet Infect Dis2002; 2: 293–302.
10.
MooreE., BeadsworthM.B., ChapondaM.Favourable one-year ART outcomes in adult Malawians with hepatitis B and C co-infection. J Infect2010; 61: 155–163.
11.
WalusansaV., KagimuM.Screening for hepatitis C among HIV positive patients at Mulago hospital in Uganda. Afr Health Sci2009; 9: 143–146.
12.
BarthR.E., HuijgenQ., TaljaardJ., HoepelmanA.I.Hepatitis B/C and HIV in sub-Saharan Africa: an association between highly prevalent infectious diseases. A systematic review and meta-analysis. Int J Infect Dis2010; 14: e1024–e1031.
13.
OcamaP., CastelnuovoB., KamyaM.R.Low frequency of liver enzyme elevation in HIV-infected patients attending a large urban treatment centre in Uganda. Int J STD AIDS2010; 21: 553–557.
14.
StabinskiL., ReynoldsS.R., OcamaP.High prevalence of liver fibrosis associated with HIV infection: a study in rural Rakai, Uganda. Antivir Ther2011; doi 10.3851/IMP1783.
15.
WedemeyerH., MannsM.P.Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead. Nat Rev Gastroenterol Hepatol2010; 7: 31–40.
16.
TerrierB., CarratF., GeriG.Low 25-OH vitamin D serum levels correlate with severe fibrosis in HIV-HCV co-infected patients with chronic hepatitis. J Hepatol2011; doi:10.1016/j.jhep.2011.01.041.
17.
BerzsenyiM.D., WoollardD.J., McLeanC.A.Down-regulation of intra-hepatic T-cell signaling associated with GB virus C in a HCV/HIV co-infected group with reduced liver disease. J Hepatol2011; doi:10.1016/j.jhep.2010.12.021.
RallónN.I., NaggieS., BenitoJ.M.Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients. AIDS2010; 24: F23–F29.
